國家衛生研究院 NHRI:Item 3990099045/10013
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 855626      在线人数 : 1272
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧:
  • 您可在西文检索词汇前后加上"双引号",以获取较精准的检索结果
  • 若欲以作者姓名搜寻,建议至进阶搜寻限定作者字段,可获得较完整数据
  • 进阶搜寻
    主页登入上传说明关于NHRI管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/10013


    题名: The prognostic impact of overall treatment time on disease outcomes of uterine cervical cancer patients: A nationwide cohort study of Taiwan
    作者: Lin, SM;Hong, JH;Ku, HY;Liu, TW;Chang, TC
    贡献者: National Institute of Cancer Research
    摘要: Results: Among the 8968 patients with FIGO stage I to IVuterine cervical cancer, 3607 patients (40%) were treated with chemoradiation therapy/ radiation therapy as initial treatment. Seventy-six percent (n Z 2751) of these patients were treated with curative radiation dose. The median time of whole radiation therapy course was 60 days (interquartile range Z 53, 69 months). The significant poor prognostic factors related to cancer specific survival (CSS) and overall survival (OS) included old age, non-squamous cancer type, high grade histology, larger tumor size, advanced FIGO stage, low hospital volume of patients’ treatment sites, and prolonged overall treatment time. After multivariate analysis with significant factors mentioned above, prolonged treatment time remained poor impact on both CSS (HR: 1.26; P Z 0.05) and OS (HR: 1.13; P Z 0.07). Every additional day more than 56 days decreased the 3-year overall survival rate by 0.8%. Further subgroup analysis disclosed that the 5-year overall survival rate for <=/ > 56 days of FIGO stage I-II and stage III-IV patients were 81% / 70% (P <0.01) and 43% / 42% (P Z 0.92), respectively. Conclusion: Prolonged treatment time of definitive CRT or RT alone for cervical cancer is detrimental for cancer specific survival and overall survival. Completion of radiation therapy treatment within eight weeks is highly recommended, especially for patients with FIGO stage I-II disease.
    日期: 2016-10-01
    關聯: International Journal of Radiation Oncology, Biology, Physics. 2016 Oct 1;96(2S, Suppl.):E301.
    Link to: http://dx.doi.org/10.1016/j.ijrobp.2016.06.1381
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0360-3016&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000387655803054
    显示于类别:[劉滄梧] 會議論文/會議摘要

    文件中的档案:

    档案 描述 大小格式浏览次数
    PUB27674318.pdf51KbAdobe PDF411检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈